About Endospan
Endospan is a Healthcare company based in Herzliya (Israel) founded in 2009, and was acquired by Artivion in May 2026. Endovascular stent graft systems for aortic aneurysm repair are developed. Endospan has raised $10 million across 1 funding round from investors including Artivion, Haisco Pharmaceutical Group and Sequoia Capital. Endospan offers products and services including NEXUS MULTIBRANCH Aortic Arch Stent Graft System. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices.
Company details
Endospan was founded in 2009 in Herzliya, Israel, as a venture capital-backed medical device startup in the cardiovascular sector. An endovascular system for aortic aneurysm repair is being developed at the pre-clinical stage. The Nexus platform is designed to support minimally invasive procedures through real-time aortic insights, incorporating two stent graft systemsHorizon and Nexuswhich remain in clinical development.
Products & Services of Endospan
Endospan offers a comprehensive portfolio of products and services, including NEXUS MULTIBRANCH Aortic Arch Stent Graft System.
Custom-made stent graft for endovascular repair of aortic arch aneurysms and stroke risk reduction.
Apps and channels of Endospan
its YouTube channel Endospan Ltd has 264 subscribers and 30 videos.
Videos from Endospan
The most watched videos on Endospan's YouTube channel, Endospan Ltd (264 subscribers). Click a video to play it here.
More on Endospan Ltd.
Funding Insights of Endospan
Endospan has successfully raised a total of $10M through 1 strategic funding round. The most recent funding activity was a Series C round of $10 million completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 1
- Last Round Series C — $10M
- First Round $10M
(Oct 2015)
- Investors Count 3
All 1 funding rounds of Endospan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2015 | $10M | Series C | – | Accelmed Ventures |
4 investors in total: 4 institutional.
Investors in Endospan
Endospan has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Artivion, Haisco Pharmaceutical Group and Sequoia Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
| accelmed-ventures.com | ||||
Pharmaceutical products are developed for various therapeutic areas. | 2009 | haisco.com | Chengdu, China | |
Aortic and cardiac surgical solutions and vascular allografts are manufactured. | 1984 | artivion.com | Kennesaw, United States |
Investor details for Endospan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Endospan
8 people are tracked at Endospan (7 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Kevin Mayberry | Chief Executive Officer | Leadership |
Ami Katz | General Manager, IL & Vice President, Operations | Leadership |
Pieter Buyl | Vice President, Sales & Marketing | Leadership |
Gadi Divald | CFO | Leadership |
Mario Lachat | Medical Director, NEXUS | Leadership |
Ian McDougall | Vice President, Research & Development | Leadership |
Jessica Kleine | Vice President, Clinical Affairs | Leadership |
Shiran M. | QA Manager | Team |
Complete people profiles for Endospan
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Endospan
3 dated milestones of Endospan across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Endospan is founded.
- Funding First funding round of $10.0M.
- Exit Acquired by Artivion.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Endospan
Complete news archive for Endospan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Endospan
Endospan was founded in 2009 and raised its 1st funding round 6 years after it was founded.
Endospan is headquartered in Herzliya, Israel. It is registered at Herzliya, Central District, Israel.
Endospan is a funded company, having raised a total of $10M across 1 funding round to date. The company's 1st funding round was a Series C of $10M, raised on Oct 2015.
Endospan was founded in 2009 in Herzliya, Israel, as a venture capital-backed medical device startup in the cardiovascular sector. An endovascular system for aortic aneurysm repair is being developed at the pre-clinical stage. The Nexus platform is designed to support minimally invasive procedures through real-time aortic insights, incorporating two stent graft systemsHorizon and Nexuswhich remain in clinical development.
Endospan offers NEXUS MULTIBRANCH Aortic Arch Stent Graft System.
Endospan has 4 investors. Key investors include Artivion, Haisco Pharmaceutical Group, Sequoia Capital, and Accelmed Ventures.
Yes. Endospan was acquired by Artivion in May 2026.